Literature DB >> 22230733

Predictors of 5-year mortality in pulmonary Mycobacterium avium-intracellulare complex disease.

Y Ito1, T Hirai, K Maekawa, K Fujita, S Imai, S Tatsumi, T Handa, H Matsumoto, S Muro, A Niimi, M Mishima.   

Abstract

SETTING: Kyoto, Japan.
OBJECTIVE: To determine predictors of 5-year mortality in pulmonary Mycobacterium avium-intracellulare complex (MAC) disease.
DESIGN: Retrospective study of 164 patients diagnosed with pulmonary MAC disease between 1999 and 2005 and followed for 5 years.
RESULTS: Overall 5-year mortality was 28.0%. Among 117 patients with microbiological outcomes, 54 were treated (treated MAC patients) and 24 were not treated and did not experience sputum culture conversion during follow-up (untreated chronic MAC patients); 39 patients were not treated and experienced sputum culture conversion. Five-year all-cause overall mortality among the 78 patients with definite MAC disease (including treated and untreated chronic MAC patients) was 25.6%. The mortality rate was 33.3% for untreated chronic MAC patients only vs. 22.2% for treated MAC patients (P = 0.30). After adjustment for clinical, microbiological and radiological confounders, independent factors for 5-year mortality were a high Charlson comorbidity index in cases with definite MAC disease (hazard ratio [HR] 1.76) and untreated chronic MAC (HR 3.08), and presence of cavitary lesions in cases with definite MAC disease (HR 1.82) and treated MAC patients (HR 3.91).
CONCLUSION: Patients with cavitary lesions require immediate treatment for sputum culture conversion and to improve their chances of survival.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22230733     DOI: 10.5588/ijtld.11.0148

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  27 in total

1.  Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care population.

Authors:  Theodore K Marras; Christopher Vinnard; Quanwu Zhang; Keith Hamilton; Jennifer Adjemian; Gina Eagle; Raymond Zhang; Engels Chou; Kenneth N Olivier
Journal:  Respir Med       Date:  2018-10-22       Impact factor: 3.415

2.  Mycobacterium Tuberculosis and Nontuberculous Mycobacteria Coinfection of the Lungs.

Authors:  Nafiye Yılmaz; Elif Yılmazel Uçar; Leyla Sağlam
Journal:  Turk Thorac J       Date:  2017-01-01

3.  Mortality among patients with pulmonary non-tuberculous mycobacteria disease.

Authors:  M Fleshner; K N Olivier; P A Shaw; J Adjemian; S Strollo; R J Claypool; L Folio; A Zelazny; S M Holland; D R Prevots
Journal:  Int J Tuberc Lung Dis       Date:  2016-05       Impact factor: 2.373

4.  The Challenge of Pulmonary Nontuberculous Mycobacterial Infection.

Authors:  Shannon Novosad; Emily Henkle; Kevin L Winthrop
Journal:  Curr Pulmonol Rep       Date:  2015-07-12

Review 5.  [Nontuberculous mycobacteria in sputum : Recommendations for diagnosis and treatment].

Authors:  J Rademacher
Journal:  Internist (Berl)       Date:  2017-11       Impact factor: 0.743

6.  Mortality after Respiratory Isolation of Nontuberculous Mycobacteria. A Comparison of Patients Who Did and Did Not Meet Disease Criteria.

Authors:  Shannon A Novosad; Emily Henkle; Sean Schafer; Katrina Hedberg; Jennifer Ku; Sarah A R Siegel; Dongseok Choi; Christopher G Slatore; Kevin L Winthrop
Journal:  Ann Am Thorac Soc       Date:  2017-07

Review 7.  Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review.

Authors:  D Rebecca Prevots; Theodore K Marras
Journal:  Clin Chest Med       Date:  2014-11-06       Impact factor: 2.878

8.  Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease.

Authors:  Seong Mi Moon; Hye Yun Park; Su-Young Kim; Byung Woo Jhun; Hyun Lee; Kyeongman Jeon; Dae Hun Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Seung-Heon Lee; Chang Ki Kim; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

Review 9.  Pulmonary Disease Due to Nontuberculous Mycobacteria: Current State and New Insights.

Authors:  Pamela J McShane; Jeffrey Glassroth
Journal:  Chest       Date:  2015-12       Impact factor: 9.410

Review 10.  Development of Drugs for Nontuberculous Mycobacterial Disease: Clinicians' Interpretation of a US Food and Drug Administration Workshop.

Authors:  Patrick A Flume; David E Griffith; James D Chalmers; Charles L Daley; Kenneth Olivier; Anne O'Donnell; Timothy Aksamit; Shannon Kasperbauer; Amy Leitman; Kevin L Winthrop
Journal:  Chest       Date:  2020-08-24       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.